Financière de Tubize S.A.
TUB
Rankning i aktier
#2212
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Aktiekurs
$203.04
Senast synkroniserad: 2026-10-21
Marknadsvärde
$9.04B
Förändring (1 dag)
-7.47%
Förändring (1 år)
-22.97%
Land
BE
Handel Financière de Tubize S.A. (TUB)
Kategori
Healthcare
Vinst för Financière de Tubize S.A. (TUB)
Vinst i Jun 2026 TTM: $116.73M
Enligt de senaste finansiella rapporterna från Financière de Tubize S.A. är företagets nuvarande vinst $116.73M. År 2023 hade företaget en vinst på $97.45M, en ökning jämfört med vinsten år 2022 som var $91.36M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Financière de Tubize S.A. från 2003 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $116.73M | 24.50% |
| 2024 | $93.76M | -3.79% |
| 2023 | $97.45M | 6.66% |
| 2022 | $91.36M | -3.90% |
| 2021 | $95.07M | -70.04% |
| 2020 | $317.28M | -0.32% |
| 2019 | $318.31M | -2.86% |
| 2018 | $327.69M | 2.60% |
| 2017 | $319.38M | 68.35% |
| 2016 | $189.71M | -16.83% |
| 2015 | $228.09M | 209.22% |
| 2014 | $73.76M | -15.46% |
| 2013 | $87.25M | -16.53% |
| 2012 | $104.53M | 15.02% |
| 2011 | $90.88M | 221.98% |
| 2010 | $28.23M | -87.95% |
| 2009 | $234.25M | -15,867.73% |
| 2008 | $-1.49M | -102.49% |
| 2007 | $59.74M | -90.49% |
| 2006 | $628.45M | 78.57% |
| 2005 | $351.93M | 105.84% |
| 2004 | $170.97M | 14.90% |
| 2003 | $148.80M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | 4,418.76% |
US
|
|
| $-3.09B | -2,744.49% |
US
|
|
| $-4.02B | -3,540.48% |
AU
|
|
| $1.95B | 1,571.03% |
NL
|
|
| - | - |
CH
|
